BX2 Stock Overview
A commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
BioXcel Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.47 |
| 52 Week High | US$3.76 |
| 52 Week Low | US$0.45 |
| Beta | 0.29 |
| 11 Month Change | -14.50% |
| 3 Month Change | -25.10% |
| 1 Year Change | -86.72% |
| 33 Year Change | -97.65% |
| 5 Year Change | -91.57% |
| Change since IPO | -94.15% |
Recent News & Updates
Recent updates
Shareholder Returns
| BX2 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -11.8% | -0.2% | 0.8% |
| 1Y | -86.7% | -16.9% | 9.1% |
Return vs Industry: BX2 underperformed the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: BX2 underperformed the German Market which returned 8.5% over the past year.
Price Volatility
| BX2 volatility | |
|---|---|
| BX2 Average Weekly Movement | 14.3% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: BX2's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: BX2's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 74 | Vimal Mehta | www.bioxceltherapeutics.com |
BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
BioXcel Therapeutics, Inc. Fundamentals Summary
| BX2 fundamental statistics | |
|---|---|
| Market cap | €20.73m |
| Earnings (TTM) | -€67.64m |
| Revenue (TTM) | €2.17m |
8.8x
P/S Ratio-0.3x
P/E RatioIs BX2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BX2 income statement (TTM) | |
|---|---|
| Revenue | US$2.28m |
| Cost of Revenue | US$2.03m |
| Gross Profit | US$251.00k |
| Other Expenses | US$71.25m |
| Earnings | -US$71.00m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.66 |
| Gross Margin | 11.03% |
| Net Profit Margin | -3,119.33% |
| Debt/Equity Ratio | -122.0% |
How did BX2 perform over the long term?
See historical performance and comparison